On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more.
Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).
